Neurocrine Biosciences (NBIX) Inventory (2017 - 2026)

Neurocrine Biosciences has reported Inventory for 10 years, with the latest figure at $64.5 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory rose 9.14% year-over-year to $64.5 million; the trailing twelve-month figure through Mar 2026 stood at $64.5 million (up 9.14% YoY), and the FY2025 full-year result was $69.0 million, up 20.21% from the prior year.
• Inventory for Q1 2026 stood at $64.5 million, down from $69.0 million in the prior quarter.
• The five-year high for Inventory was $69.3 million in Q3 2025, with the low at $28.8 million in Q3 2023.
• Historically, Inventory has averaged $45.0 million across 5 years, with a median of $38.3 million in 2023.
• Annual changes were most pronounced in 2023 — Inventory fell 22.16% — and 2024, when it surged 59.03%.
• Neurocrine Biosciences' Inventory stood at $35.1 million in 2022, then rose by 9.12% to $38.3 million in 2023, then jumped by 49.87% to $57.4 million in 2024, then increased by 20.21% to $69.0 million in 2025, then decreased by 6.52% to $64.5 million in 2026.
• The last three Inventory figures came in at $64.5 million (Q1 2026), $69.0 million (Q4 2025), and $69.3 million (Q3 2025), per Business Quant data.